鉄のケレーションは,冠動脈疾患の患者の内皮機能を改善します
S J Duffy1, E S Biegelsen, M Holbrook
1Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA.
Circulation
|June 13, 2001
まとめ
デフェロキサミンで鉄の貯蔵量を減らすことで,冠動脈疾患の患者の酸化窒素の機能が改善され,鉄が動脈硬化における血管機能不全に寄与することを示唆しています.
科学分野:
- 心血管科学 心血管科学
- 酸化ストレス研究 酸化ストレス研究
- 血管生物学 血管生物学
背景:
- 鉄の貯蔵量の増加は,心血管疾患の増加と相関しています.
- レドックス活性鉄は酸化ストレスと内皮機能障害を促進します.
- 動脈硬化症は,酸化窒素 (NO) の作用の低下と関連しています.
研究 の 目的:
- 血管内の鉄貯蔵量を減らすことで,内皮機能不全が逆転するかどうかを調査する.
- 冠動脈疾患を患っている患者で,鉄調合剤デフェロキサミンの有効性を試験する.
主な方法:
- 冠動脈疾患の患者にデフェロキサミン (500 mg 動脈内投与) を投与した.
- 静脈閉塞プレシスモグラフィーとメタホリンを用いて血管運動機能を評価した.
- NO合成阻害またはヒドロキシルラジカルスキャバンジングによる患者および健康なボランティアにおける応答の比較.
主要な成果:
- 冠動脈疾患の患者は,内皮に依存した血管拡張の障害を示した.
- デフェロキサミンは血清鉄濃度を低下させ,メタコリン誘発の血管拡張を改善した.
- デフェロキサミンは,健康なボランティアの血管拡張や,ナトリウムニトロプロシドに対する反応に影響を与えませんでした.
結論:
- デフェロキサミンは,冠動脈疾患患者の酸化窒素による血管拡張を強める.
- 鉄の利用可能性は,動脈硬化症における窒素酸化物の作用の低下に寄与する.
- 血管鉄をターゲットにすることは,動脈硬化症の治療戦略かもしれません.
関連する概念動画
Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Coronary Artery Disease V: Interprofessional Care
452
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
Angina IV: Management
496
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
496


